The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab

Several Bevacizumab products are approved for clinical use, with many others in late-stage clinical development worldwide. To aid the harmonization of potency assessment across different Bevacizumab products, the first World Health Organization (WHO) International Standard (IS) for Bevacizumab has b...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Haiyan, Harikumar, Parvathy, Atkinson, Eleanor, Rigsby, Peter, Wadhwa, Meenu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615914/
https://www.ncbi.nlm.nih.gov/pubmed/34827607
http://dx.doi.org/10.3390/biom11111610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615914/
https://www.ncbi.nlm.nih.gov/pubmed/34827607
http://dx.doi.org/10.3390/biom11111610

Ejemplares similares